Targets › WRN
3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout May 2027.
Multifunctional enzyme that has magnesium and ATP-dependent 3'-5' DNA-helicase activity on partially duplex substrates. Also has 3'->5' exonuclease activity towards double-stranded (ds)DNA with a 5'-overhang. (UniProt, Q14191)
Open in Phaseline: the race on WRN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vividion Therapeutics | VVD-133214 WRN protein inhibitor | WRN | Phase 2 | Colorectal Adenocarcinoma; Advanced Solid Tumors | May 2027 |
| Eikon Therapeutics | EIK1005 Werner helicase inhibitor | WRN | Phase 1 | Advanced Solid Tumors | Mar 2029 |
| Nimbus Wadjet | NDI-219216 WRN helicase inhibitor | WRN | Phase 1 | Advanced Solid Tumors Cancer | Oct 2031 |
Advanced Solid Tumors (2) Advanced Solid Tumors Cancer (1) Colorectal Adenocarcinoma (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.